| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
Purity: ≥98%
CCG215022 is a potent GRK2 and GRK5 inhibitor that exhibited nanomolar IC50 values against both GRK2 and GRK5 and good selectivity against other closely related kinases such as GRK1 and PKA. Murine cardiomyocytes treated with CCG215022 showed significantly increased contractility at 20-fold lower concentrations than paroxetine, an inhibitor with more modest selectivity for GRK2. G protein-coupled receptor kinases (GRKs) regulate cell signaling by initiating the desensitization of active G protein-coupled receptors. The two most widely expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus represent important targets for the development of novel therapeutic drugs.
| ln Vitro |
When it comes to both GRK2 and GRK5, CCG215022 exhibits nanomolar potency and is at least 20 times more potent than propecia. CCG215022 demonstrates nanomolar IC50 values against both GRK2 and GRK5, along with good selectivity against other closely related kinases like GRK1 and PKA, during a GRK2 structure-based drug design campaign. When CCG215022 is applied to murine cardiomyocytes, contractility is markedly increased at 20-fold lower concentrations than when paroxetine, an inhibitor with a more moderate selectivity for GRK2, is used[1].
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C₂₆H₂₂FN₇O₃
|
|
|---|---|---|
| Molecular Weight |
499.5
|
|
| Exact Mass |
499.176
|
|
| CAS # |
1813527-81-9
|
|
| Related CAS # |
|
|
| PubChem CID |
118888941
|
|
| Appearance |
White to gray solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
783.2±60.0 °C at 760 mmHg
|
|
| Flash Point |
427.4±32.9 °C
|
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
|
| Index of Refraction |
1.691
|
|
| LogP |
1.8
|
|
| Hydrogen Bond Donor Count |
5
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
37
|
|
| Complexity |
915
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
BLMBNKDQXGINRE-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C26H22FN7O3/c1-14-22(25(36)32-17-6-8-21-16(10-17)12-30-34-21)23(33-26(37)31-14)15-5-7-20(27)19(11-15)24(35)29-13-18-4-2-3-9-28-18/h2-12,23H,13H2,1H3,(H,29,35)(H,30,34)(H,32,36)(H2,31,33,37)
|
|
| Chemical Name |
4-[4-fluoro-3-(pyridin-2-ylmethylcarbamoyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.01 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0020 mL | 10.0100 mL | 20.0200 mL | |
| 5 mM | 0.4004 mL | 2.0020 mL | 4.0040 mL | |
| 10 mM | 0.2002 mL | 1.0010 mL | 2.0020 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Ligand interactions in the active sites of GRK5 and GRK2.J Biol Chem.2015 Aug 21;290(34):20649-59. |
|---|
 Rational design of improved GRK inhibitors.J Biol Chem.2015 Aug 21;290(34):20649-59. |
 Model of GRK4 subfamily membrane interactions.J Biol Chem.2015 Aug 21;290(34):20649-59. |
 Crystal structure of GRK5 in complex with CCG215022.J Biol Chem.2015 Aug 21;290(34):20649-59. |
|---|
 Increased adrenergic contractility in myocytes treated with GRK2 inhibitors.
Inhibition of GRKs and PKA by CCG215022.J Biol Chem.2015 Aug 21;290(34):20649-59. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
